These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32407995)

  • 1. Editorial Commentary: What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?
    Brunham LR; Mancini GBJ
    Trends Cardiovasc Med; 2021 May; 31(4):216-217. PubMed ID: 32407995
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.
    Lee S; Akioyamen LE; Aljenedil S; Rivière JB; Ruel I; Genest J
    Eur J Prev Cardiol; 2019 Aug; 26(12):1262-1270. PubMed ID: 30755017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial commentary: Exciting new therapies for familial hypercholesterolemia, but we can also make better use of some old ones.
    Walsh JP
    Trends Cardiovasc Med; 2023 Apr; 33(3):180-181. PubMed ID: 35091044
    [No Abstract]   [Full Text] [Related]  

  • 4. Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.
    Alves AC; Alonso R; Diaz-Diaz JL; Medeiros AM; Jannes CE; Merchan A; Vasques-Cardenas NA; Cuevas A; Chacra AP; Krieger JE; Arroyo R; Arrieta F; Schreier L; Corral P; Bañares VG; Araujo MB; Bustos P; Asenjo S; Stoll M; Dell'Oca N; Reyes M; Ressia A; Campo R; Magaña-Torres MT; Metha R; Aguilar-Salinas CA; Ceballos-Macias JJ; Morales ÁJR; Mata P; Bourbon M; Santos RD
    Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):2508-2515. PubMed ID: 32757650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Rizos CV; Elisaf MS; Skoumas I; Tziomalos K; Kotsis V; Rallidis L; Garoufi A; Athyros VG; Skalidis E; Kolovou G; Koutagiar I; Papagianni M; Antza C; Katsiki N; Ganotakis E; Liberopoulos EN
    Atherosclerosis; 2018 Oct; 277():308-313. PubMed ID: 30270064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening and management of familial hypercholesterolemia.
    Santos RD
    Curr Opin Cardiol; 2019 Sep; 34(5):526-530. PubMed ID: 31393421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms.
    Kallapur A; Sallam T
    Trends Cardiovasc Med; 2023 Apr; 33(3):170-179. PubMed ID: 34968676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
    Miname MH; Bittencourt MS; Nasir K; Santos RD
    Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Is Familial Hypercholesterolemia, and Why Does It Matter?
    Khera AV; Hegele RA
    Circulation; 2020 Jun; 141(22):1760-1763. PubMed ID: 32479201
    [No Abstract]   [Full Text] [Related]  

  • 14. Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia.
    Mizuta MH; Santos RD
    Atherosclerosis; 2022 Oct; 358():57-59. PubMed ID: 36049962
    [No Abstract]   [Full Text] [Related]  

  • 15. First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated.
    Stock J
    Atherosclerosis; 2019 Nov; 290():138-139. PubMed ID: 31610884
    [No Abstract]   [Full Text] [Related]  

  • 16. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic approach to childhood hypercholesterolemia.
    Shamir R; Feig JE; Fisher EA
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):649-55. PubMed ID: 18084159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?
    Harada-Shiba M
    Atherosclerosis; 2019 May; 284():218-220. PubMed ID: 30894250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.